Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Dual Diagn ; 16(1): 120-139, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31479625

RESUMEN

Objectives: Posttraumatic stress disorder (PTSD) is a potentially debilitating mental health problem. There has been a recent surge of interest regarding the use of cannabinoids in the treatment of PTSD. We therefore sought to systematically review and assess the quality of the clinical evidence of the effectiveness of cannabinoids for the treatment of PTSD. Method: We included all studies published until December 2018 where a patient has had PTSD diagnosed and had been prescribed or were using a cannabinoid for the purpose of reducing PTSD symptoms. Our primary outcome measure was the reduction in PTSD symptoms using a validated instrument. In the absence of randomized controlled trials, we included the next best available levels of evidence including observational and retrospective studies and case reports. We assessed risk of bias and quality using validated tools appropriate for the study design. Results: We included 10 studies in this review, of which only one study was a pilot randomized, double-blind, placebo-controlled, crossover clinical trial. Every identified study had medium to high risk of bias and was of low quality. We found that cannabinoids may decrease PTSD symptomology, in particular sleep disturbances and nightmares. Conclusions: Most studies to date are small and of low quality, with significant limitations to the study designs precluding any clinical recommendations about its use in routine clinical practice. Evidence that cannabinoids may help reduce global PTSD symptoms, sleep disturbances, and nightmares indicates that future well-controlled, randomized, double-blind clinical trials are highly warranted.PROSPERO registration number: 121646.


Asunto(s)
Moduladores de Receptores de Cannabinoides/farmacología , Marihuana Medicinal/farmacología , Preparaciones de Plantas/farmacología , Trastornos por Estrés Postraumático/tratamiento farmacológico , Humanos
2.
Sci Rep ; 8(1): 7568, 2018 05 15.
Artículo en Inglés | MEDLINE | ID: mdl-29765102

RESUMEN

Acute nicotine abstinence in cigarette smokers results in deficits in performance on specific cognitive processes, including working memory and impulsivity which are important in relapse. Cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, has shown pro-cognitive effects and preliminary evidence has indicated it can reduce the number of cigarettes smoked in dependent smokers. However, the effects of CBD on cognition have never been tested during acute nicotine withdrawal. The present study therefore aimed to investigate if CBD can improve memory and reduce impulsivity during acute tobacco abstinence. Thirty, non-treatment seeking, dependent, cigarette smokers attended two laboratory-based sessions after overnight abstinence, in which they received either 800 mg oral CBD or placebo (PBO), in a randomised order. Abstinence was biologically verified. Participants were assessed on go/no-go, delay discounting, prose recall and N-back (0-back, 1-back, 2-back) tasks. The effects of CBD on delay discounting, prose recall and the N-back (correct responses, maintenance or manipulation) were null, confirmed by a Bayesian analysis, which found evidence for the null hypothesis. Contrary to our predictions, CBD increased commission errors on the go/no-go task. In conclusion, a single 800 mg dose of CBD does not improve verbal or spatial working memory, or impulsivity during tobacco abstinence.


Asunto(s)
Cannabidiol/administración & dosificación , Conducta Impulsiva/efectos de los fármacos , Memoria/efectos de los fármacos , Tabaquismo/psicología , Adulto , Teorema de Bayes , Cannabidiol/farmacología , Femenino , Humanos , Masculino , Memoria a Corto Plazo/efectos de los fármacos , Distribución Aleatoria , Memoria Espacial/efectos de los fármacos , Adulto Joven
3.
Psychopharmacology (Berl) ; 235(2): 459-466, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-29085980

RESUMEN

RATIONALE: Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome. OBJECTIVES: The objective of this study is to investigate whether psilocybin, recently shown to rapidly improve mood in treatment-resistant depression (TRD), alters patients' emotional processing biases. METHODS: Seventeen patients with treatment-resistant depression completed a dynamic emotional face recognition task at baseline and 1 month later after two doses of psilocybin with psychological support. Sixteen controls completed the emotional recognition task over the same time frame but did not receive psilocybin. RESULTS: We found evidence for a group × time interaction on speed of emotion recognition (p = .035). At baseline, patients were slower at recognising facial emotions compared with controls (p < .001). After psilocybin, this difference was remediated (p = .208). Emotion recognition was faster at follow-up compared with baseline in patients (p = .004, d = .876) but not controls (p = .263, d = .302). In patients, this change was significantly correlated with a reduction in anhedonia over the same time period (r = .640, p = .010). CONCLUSIONS: Psilocybin with psychological support appears to improve processing of emotional faces in treatment-resistant depression, and this correlates with reduced anhedonia. Placebo-controlled studies are warranted to follow up these preliminary findings.


Asunto(s)
Trastorno Depresivo Resistente al Tratamiento/tratamiento farmacológico , Emociones/efectos de los fármacos , Reconocimiento Facial/efectos de los fármacos , Alucinógenos/uso terapéutico , Psilocibina/uso terapéutico , Sistemas de Apoyo Psicosocial , Adulto , Trastorno Depresivo Resistente al Tratamiento/psicología , Emociones/fisiología , Expresión Facial , Reconocimiento Facial/fisiología , Femenino , Estudios de Seguimiento , Alucinógenos/farmacología , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Psilocibina/farmacología , Resultado del Tratamiento , Adulto Joven
4.
Psychol Med ; 47(15): 2708-2719, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28558859

RESUMEN

BACKGROUND: Cannabis and tobacco have contrasting cognitive effects. Smoking cannabis with tobacco is prevalent in many countries and although this may well influence cognitive and mental health outcomes, the possibility has rarely been investigated in human experimental psychopharmacological research. METHOD: The individual and interactive effects of cannabis and tobacco were evaluated in 24 non-dependent cannabis and tobacco smokers in a randomized, placebo-controlled, double-blind, 2 (cannabis, placebo) × 2 (tobacco, placebo) crossover design. Verbal memory (prose recall), working memory (WM) performance including maintenance, manipulation and attention (N-back), psychotomimetic, subjective and cardiovascular measures were recorded on each of four sessions. RESULTS: Cannabis alone impaired verbal memory. A priori contrasts indicated that tobacco offset the effects of cannabis on delayed recall. However, this was not supported by linear mixed model analysis. Cannabis load-dependently impaired WM. By contrast, tobacco improved WM across all load levels. The acute psychotomimetic effects and ratings of 'stoned' and 'dizzy' induced by cannabis were not altered by tobacco. Cannabis and tobacco had independent effects on increasing heart rate and interacting effects on increasing diastolic blood pressure. CONCLUSIONS: Relative to placebo, acute cannabis impaired verbal memory and WM. Tobacco enhanced performance on WM, independently of cannabis. Moreover, we found some preliminary evidence that tobacco may offset the effects of cannabis on delayed, but not immediate, verbal recall. In contrast, the psychotomimetic and subjective effects of cannabis were unaffected by tobacco co-administration. By reducing the cognitive impairment from cannabis, tobacco co-administration may perpetuate use despite adverse health consequences.


Asunto(s)
Atención/efectos de los fármacos , Presión Sanguínea/efectos de los fármacos , Cannabinoides/farmacología , Fumar Cigarrillos , Disfunción Cognitiva/inducido químicamente , Disfunción Cognitiva/prevención & control , Frecuencia Cardíaca/efectos de los fármacos , Fumar Marihuana/efectos adversos , Memoria a Corto Plazo/efectos de los fármacos , Recuerdo Mental/efectos de los fármacos , Nicotina/farmacología , Adulto , Cannabinoides/administración & dosificación , Cannabinoides/efectos adversos , Fumar Cigarrillos/efectos adversos , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Masculino , Nicotina/administración & dosificación , Nicotina/efectos adversos , Adulto Joven
5.
Psychopharmacology (Berl) ; 232(14): 2503-17, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25757672

RESUMEN

RATIONALE: Drug addiction may be characterised by a hypersensitivity to drug rewards and a hyposensitivity to non-drug rewards. This imbalance may become further polarised during acute abstinence. OBJECTIVES: (i) Examine the differences between dependent and occasional smokers in choices for, motivation for and self-reported wanting and liking of cigarette and non-drug rewards. (ii) Examine the effects of 12-h nicotine abstinence on these metrics. METHODS: Dependent (n = 20) and occasional, non-dependent smokers (n = 20) were tested after ad libitum smoking and ≥12-h of nicotine abstinence. A novel task was developed (Drug, Reward and Motivation-Choice (DReaM-Choice)) in which different rewards (cigarettes, music and chocolate) could be won. In each trial, participants chose between two rewards and then could earn the chosen reward via repeated button-pressing. Participants subsequently 'consumed' and rated subjective liking of the rewards they had won. RESULTS: Compared with occasional smokers, dependent smokers made more choices for (p < 0.001), pressed more for (p = 0.046) and reported more wanting (p = 0.007) and liking (p < 0.001) of cigarettes, and also made fewer choices for chocolate (p = 0.005). There were no differences between the groups on button-pressing for chocolate or music. However, the balance between drug and non-drug reward processing was different between the groups across all metrics. Twelve-hour nicotine abstinence led to more cigarette choices (p < 0.001) and fewer music choices (p = 0.042) in both groups. CONCLUSIONS: Nicotine dependence was associated with a hypersensitivity to cigarette rewards, but we found little evidence indicating a hyposensitivity to non-drug rewards. Our findings question the moderating influence of dependence on how acute nicotine abstinence affects reward processing.


Asunto(s)
Recompensa , Síndrome de Abstinencia a Sustancias/psicología , Tabaquismo/psicología , Monóxido de Carbono/metabolismo , Conducta de Elección/efectos de los fármacos , Ansia , Estudios Cruzados , Depresión/psicología , Femenino , Humanos , Masculino , Motivación/efectos de los fármacos , Nicotina/farmacología , Placer/efectos de los fármacos , Desempeño Psicomotor/efectos de los fármacos , Lectura , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA